Twist Bioscience Co. (NASDAQ:TWST) COO Sells $121,511.74 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,422 shares of Twist Bioscience stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $50.17, for a total value of $121,511.74. Following the sale, the chief operating officer now directly owns 272,044 shares in the company, valued at $13,648,447.48. This trade represents a 0.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Patrick John Finn also recently made the following trade(s):

• On Friday, January 3rd, Patrick John Finn sold 229 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total value of $10,440.11.
• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total value of $496,320.00.
• On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total value of $278,259.40.
• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total value of $111,422.36.

Twist Bioscience Stock Down 3.4 %

Shares of Twist Bioscience stock traded down $1.84 during mid-day trading on Monday, reaching $52.23. 580,062 shares of the stock traded hands, compared to its average volume of 722,758. The business has a 50-day moving average of $47.41 and a 200 day moving average of $46.37. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The stock has a market capitalization of $3.10 billion, a PE ratio of -14.51 and a beta of 1.85.

Wall Street Analyst Weigh In

TWST has been the subject of a number of research analyst reports. Wolfe Research started coverage on Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. TD Cowen reissued a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Scotiabank boosted their target price on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. Evercore ISI boosted their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, Barclays lowered their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average target price of $51.90.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds have recently made changes to their positions in the company. Signaturefd LLC raised its holdings in shares of Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Twist Bioscience by 2.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock valued at $734,000 after purchasing an additional 363 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after purchasing an additional 381 shares in the last quarter. D.A. Davidson & CO. grew its position in shares of Twist Bioscience by 3.5% in the third quarter. D.A. Davidson & CO. now owns 19,618 shares of the company’s stock valued at $886,000 after purchasing an additional 664 shares in the last quarter. Finally, Stifel Financial Corp grew its position in shares of Twist Bioscience by 11.8% in the third quarter. Stifel Financial Corp now owns 6,967 shares of the company’s stock valued at $315,000 after purchasing an additional 734 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.